Identification of lncRNA–miRNA–mRNA regulatory network associated with epithelial ovarian cancer cisplatin‐resistant

Zhao, Xin; Tang, Dongyang; Zuo, Xu; Zhang, Tiandong; Wang, Cheng

doi:10.1002/jcp.28587

Cited by 44 publications

(33 citation statements)

References 41 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, NCAM1 may be a useful biomarker and therapeutic target for acute myeloid leukemia (41), the follicular variant of papillary thyroid carcinoma (42) and breast cancer (43). Although NCAM1 has been associated with cisplatin resistance in ovarian cancer (44,45), the in vitro expression of NCAM improved the response of multiple myeloma cells to Bortezomib (Btz) treatment (46). Consistent with this, the present study revealed that NCAM upregulation was associated with improved patient OS time outcomes.…”

Section: Discussionsupporting

confidence: 79%

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

Huang

Wei

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer and has a poor 5 year survival rate (<10%). Cisplatin is one of the most effective chemotherapeutic treatments for LUAD, even though it is of limited overall utility due to acquired drug resistance. To identify possible genetic targets for the mitigation of cisplatin resistance, gene expression data from cisplatin-resistant cell lines were integrated with patient information. Expression data for cisplatin-resistant and cisplatin-sensitive A549 cell lines were obtained from the Gene Expression Omnibus database, while LUAD patient data was obtained from The Cancer Genome Atlas (TCGA) database. Differentially expressed mRNAs (DEmRNAs), microRNAs (DEmiRNAs) and long non-coding RNAs (DElncRNAs) were identified between the cisplatin-sensitive and cisplatin-resistant cells. Using the TCGA patient data, 33 DEmRNAs associated with survival were identified. A total of 74 DElncRNAs co-expressed with the survival-associated DEmRNAs, and 11 DEmiRNAs that regulated the survival-associated DEmRNAs, were also identified. A competing endogenous RNA (ceRNA) network was constructed based on the aforementioned results, which included 17 survival-associated DEmRNAs, 9 DEmiRNAs and 16 DElncRNAs. This network revealed 8 ceRNA pathway axes possibly associated with cisplatin resistance in A549 cells. Specifically, the network suggested that the lncRNAs HOXD-AS2, LINC01123 and FIRRE may act as ceRNAs to increase cisplatin resistance in human LUAD cells. Therefore, it was speculated that these lncRNAs represent potentially rewarding research targets.

show abstract

Section: Discussionsupporting

confidence: 79%

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

Huang

Wei

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Improvements in bioinformatic analyses methods and applications of high throughput sequencing technology have identified numerous aberrantly expressed lncRNAs in cancers. 12,13 It should be noted lncRNAs play crucial roles in regulating CC carcinogenesis. Previous work found lncRNA SNHG7 was increased expression in CC tissues and correlated with poor overall survival.…”

Section: Discussionmentioning

confidence: 99%

<p>LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis</p>

Zhao¹,

Yang²,

Long³

2020

OTT

View full text Add to dashboard Cite

Introduction: Cervical cancer (CC) is a major health threat to women worldwide. Long non-coding RNA (lncRNA) has been reported to play crucial roles in regulating carcinogenesis, including CC. Methods: In this work, levels of lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) in CC cell lines and normal cell lines were analyzed with quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) method. Effects of FOXP4-AS1 on CC cellular behaviors including proliferation, migration, and invasion were explored. Bioinformatic prediction tools and luciferase activity reporter assay were conducted to explore the downstream molecules for FOXP4-AS1. Results: We found FOXP4-AS1 expression was significantly higher in CC cell lines than in normal cell line. Functionally, force FOXP4-AS1 expression increased CC cell proliferation, migration, and invasion, while FOXP4-AS1 knockdown caused opposite effects. Mechanistically, we found FOXP4-AS1 acts as competing endogenous RNA (ceRNA) for microRNA-136-5p (miR-136-5p) to regulate chromobox 4 (CBX4) expression. Discussion: These findings indicated FOXP4-AS1 plays an oncogenic role in CC, which may provide novel therapeutic biomarker against CC.

show abstract

“…In fact, several reports have suggested that the ceRNA networks are related to the occurrence and progression of tumors, such as hepatocellular carcinoma [28], prostate cancer [29] and glioblastoma [30]. However, there have been few reports regarding the ceRNA regulatory networks and their involvement in drug resistance except for chemoesistance to osteosarcoma [23] and cisplatin-resistance to epithelial ovarian cancer [31]. In our study, we present a comprehensive perspective on the potential function of lncRNAs and mRNAs.…”

Section: Discussionmentioning

confidence: 91%

Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer

Kong¹,

Hu²,

Yuan³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Drug resistance to chemotherapeutic drugs or targeted medicines is an obstacle encountered in the treatment of non-small-cell lung cancer (NSCLC). However, the mechanisms of competing endogenous RNA (ceRNA) on the drug resistance in NSCLC are rarely reported. In this paper, the comprehensive expression profiles of lncRNAs and mRNAs in drug-resistant NSCLC cells were obtained by RNA sequencing. Methods: The dysregulated lncRNAs, miRNAs and mRNAs in drug-resistant NSCLC cell lines were identified by RNA-sequencing and bioinformatics methods. Results: A total of 39 dysregulated lncRNAs and 650 dysregulated mRNAs were identified between drug-resistant NSCLC cell lines and their parental cell lines. Additionally, 33 lncRNA-miRNA-mRNA pathways in the ceRNA network in drug-resistant NSCLC were constructed through bioinformatics methods and ceRNA regulatory rules. These comprised 12 dysregulated lncRNAs, five dysregulated miRNAs, and eight dysregulated mRNAs. In addition, lncRNA ATP2B1/miR-222-5p/TAB2 and lncRNA HUWE1/miR-222-5p/TAB2 were identified as potential ceRNA networks involved in drug resistance to NSCLC. Conclusions: The current study provides a promising therapeutic strategy against the lncRNA-miRNA-mRNA ceRNA regulatory network for NSCLC treatment and deepens our comprehension of the ceRNA regulatory mechanisms related to drug resistance to NSCLC.

show abstract

Identification of lncRNA–miRNA–mRNA regulatory network associated with epithelial ovarian cancer cisplatin‐resistant

Cited by 44 publications

References 41 publications

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

A putative competing endogenous RNA network in cisplatin‑resistant lung adenocarcinoma cells identifying potentially rewarding research targets

<p>LncRNA FOXP4-AS1 Is Involved in Cervical Cancer Progression via Regulating miR-136-5p/CBX4 Axis</p>

Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer

Contact Info

Product

Resources

About